মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

krka d.d., novo mesto - cholecalciferolum - comprimate - 500 ui

মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

csp "ucf borsceagov" sap - comprimate - 100 mg

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

salutas pharma gmbh - austria - combinatii (paracetamolum+phenylephrinum) - pulb. pt. sol. orala - 500mg/12,2mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

salutas pharma gmbh - austria - combinatii (paracetamolum+phenylephrinum) - pulb. pt. sol. orala - 1000mg/12,2mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

salutas pharma gmbh - austria - combinatii (paracetamolum+phenylephrinum) - pulb. pt. sol. orala - 500mg/12,2mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

salutas pharma gmbh - austria - combinatii (paracetamolum+phenylephrinum) - pulb. pt. sol. orala - 1000mg/12,2mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberculoză, rezistentă la diferite medicamente - antimicobacteriene - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 și 5. trebuie luate în considerare ghidurile oficiale referitoare la utilizarea adecvată a medicamentelor antibacteriene.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - agenți antineoplazici - topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5. topotecan în asociere cu cisplatină este indicat pentru pacienții cu carcinom de col uterin recurente după radioterapie și pentru pacienții cu stadiul ivb boala. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

teva b.v. - topotecan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - agenți antineoplazici - topotecan monotherapy is indicated for the treatment of: , patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy;, patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. , topotecan în asociere cu cisplatină este indicat pentru pacienții cu carcinom de col uterin recurente după radioterapie și pentru pacienții cu stadiul ivb boala. pacienții cu expunere anterioară la cisplatină necesită un tratament susținut interval liber pentru a justifica tratamentul cu combinația.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agenți antineoplazici - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.